Completed Enrollment

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

I3Y-MC-JPEI -

The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Prostate Cancer
What the trial is testing?
Abemaciclib, Darolutamide, LHRH agonist/antagonist
Could I receive a Placebo?
No
Enrollment Goal
10
Trial Dates
Jan 12, 2024 - Jul 2026
How long will I be in the trial?
Participation may last up to 32 months.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have a diagnosis of prostate cancer that has spread to other parts of the body and no longer responds to treatment to lower testosterone

  • Have blood test results that show that body organs are working appropriately

  • Be well enough to walk and do light work

Participants Must Not:

  • Have had certain prior treatments for prostate cancer

  • Have serious medical conditions, such as heart disease

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources